(UroToday.com) In the second Prostate Cancer session at this year’s Society of Urologic Oncology virtual annual meeting, Dr. Maha Hussain discussed the role of poly ADP ribose polymerase (PARP) inhibitors, particularly olaparib, in metastatic castration-resistant prostate cancer.